Indeed, a meta-analysis of patients with mild or moderate CKD has shown that intervention with a mineralocorticoid receptor antagonist (MRA) as adjunct to RAASi reduces blood pressure [13]. The gene discussed is NR3C2; the disease is chronic kidney disease.